

14 August 2015

Announcements

National Stock Exchange of Australia

PO Box 283

NEWCASTLE NSW 2300

Market Announcement – Update on Nasdaq cross-listing

Further to its announcement on 5 March 2015 whereby iQnovate Limited (NSX:IQN) (the Company) announced its intention to commence the process to list the Company's depository receipts on the Nasdaq Capital Markets USA, the company would like to further announce that it has reserved the Nasdaq ticker symbol "IQN" for the period until 3 March 2017. The company is now in the planning and preparatory phase with its US legal and corporate advisors to address the listing criteria of the Nasdaq Capital Markets USA.

The Company will provide further updates on the listing process in due course.



Kelvin Boateng

Company Secretary

Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with IQnovate's business can be found in its periodic filings with the National Stock Exchange of Australia.

SOURCE IQnovate Limited

IQnovate Ltd is a life science organisation, providing intellectual property asset management services and scientific advice to the global Biopharmaceutical industry.

Whether the asset is a pharmaceutical, medical device, technology platform or a compound in development, iQnovate will effectively manage your asset through its complete life cycle, from clinical trials right through to maturity.

iQnovate clients are pharmaceutical, biotechnology, medical device companies as well as financial institutions, academic and government organisations.